<DOC>
	<DOCNO>NCT02050178</DOCNO>
	<brief_summary>This open-label Phase 1b dose-escalation study ass safety , tolerability , PK OMP-54F28 combine nab-paclitaxel gemcitabine . OMP-54F28 administered IV Days 1 15 28-day cycle . Nab-paclitaxel ( 125 mg/m2 ) gemcitabine ( 1000 mg/m2 ) administer IV Days 1 , 8 , 15 cycle . The plan dose level OMP-54F28 3.5 mg/kg 7.0 mg/kg .</brief_summary>
	<brief_title>Dose Escalation Study OMP-54F28 Combination With Nab-Paclitaxel Gemcitabine Patients With Previously Untreated Stage IV Pancreatic Cancer</brief_title>
	<detailed_description>Depending safety study , additional low intermediate dose level may evaluate . Depending emerge safety data Phase 1a study 54F28-001 continue dose escalation , additional high dose level OMP-54F28 may evaluate study . No dose escalation OMP-54F28 allow within dose cohort . Once maximum tolerate dose ( MTD ) maximum administer dose ( MAD ) determine , 10 patient may enrol cohort-expansion phase well characterize safety , tolerability PK OMP-54F28 combine nab-paclitaxel gemcitabine . Up approximately 34 patient may enrol study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Signed Informed Consent Form Age ≥18 year Histologically document Stage IV ductal adenocarcinoma pancreas Availability FFPE tumor tissue , either archival obtain study entry fresh biopsy Tumor tissue fine needle aspiration acceptable . ECOG performance status 0 1 Adequate hematologic endorgan function Evaluable measurable disease per RECIST v1.1 For woman childbearing potential men partner childbearing potential , agreement use two effective form contraception Prior therapy Day 1 Cycle 1 treatment Stage IV pancreatic cancer Prior adjuvant therapy treatment ductal adenocarcinoma pancreas Known hypersensitivity component study treatment Known brain metastasis , uncontrolled seizure disorder , active neurologic disease Leptomeningeal disease manifestation cancer Active infection require antibiotic Bisphosphonate therapy symptomatic hypercalcemia Known history clinically significant liver disease , include active viral hepatitis cirrhosis Significant intercurrent illness include , limited , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnancy , lactation , breastfeed Known HIV infection Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Concurrent use therapeutic warfarin History interstitial lung disease , sarcoidosis , silicosis , idiopathic pulmonary fibrosis , pulmonary hypersensitivity pneumonitis New York Heart Association Classification III IV Known clinically significant gastrointestinal disease include , limited , inflammatory bowel disease Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior first dose study treatment anticipation need major surgical procedure course study Osteoporosis base Tscore &lt; 2.5 leave right total hip , leave right femoral neck lumbar spine ( L1L4 ) determine DEXA scan Bone metastases one following : Prior history pathologic fracture Lytic lesion require impend orthopedic intervention Lack treatment bisphosphonate denosumab Treatment thiazolidinedione PPAR gamma inhibitor ; e.g . Actos® ( pioglitazone ) Avandia® ( rosiglitazone ) Active treatment oral IV glucocortocoid ≥4 week daily dose equivalent great 7.5 mg oral prednisone Fasting βCTX &gt; 1000 pg/mL Metabolic bone disease , hyperparathyroidism , Paget 's disease osteomalacia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Stage IV Pancreatic Cancer</keyword>
</DOC>